Concepedia

Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)

A. Degen, Michael Weichenthal, Selma Ugurel, Uwe Trefzer, Katharina Kilian, Claus Garbe, Friederike Egberts, Lidía M. Poppe, Axel Hauschild, Ralf Gutzmer

JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2013 · 12 citations · 16 references

DOI

Abstract

The combination of sorafenib/pegylated interferon alpha-2b caused more cutaneous side effects than have been reported for single agents. Despite intensive dermatologic management of the cutaneous side effects 24 % of patients required a dose modification.

References

16

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 870 citations · Full text

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 638 citations

, , +7

Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon

Helen Gogas, J. Ioannovich, Urania Dafni et al. · New England Journal of Medicine · 2006 · 560 citations

Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

Julien Autier, Bernard Escudier, Janine Wechsler et al. · Archives of Dermatology · 2008 · 222 citations